Dr. Kore K. Liow, MD
Neurology (Neurology Physician)
2230 Liliha St Ste 104
Honolulu, HI 96817
Who else practices at this address →
Honolulu County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 391
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
HI license MD12149 · KS license 0428786
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Hawaii PAcific Neuroscience LLC (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 391
- Services billed
- 7,362
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 419 | 232 |
| Measurement of brain wave activity (eeg), awake and asleep | 293 | 220 |
| New patient office or other outpatient visit, 45-59 minutes | 123 | 123 |
| Established patient office or other outpatient visit, 40-54 minutes | 86 | 82 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 61 | 60 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 32 |
| Measurement of brain wave activity (eeg), awake and drowsy | 40 | 38 |
| Sleep study in sleep lab (6 years or older) | 13 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 57 payments worth $4,696 in total to this clinician.
| UCB SA | $2,500 |
|---|---|
| F. Hoffmann-la Roche AG | $805 |
| AbbVie Inc. | $356 |
| UCB, Inc. | $144 |
| Inspire Medical Systems, Inc. | $124 |
| Eisai Inc. | $121 |
| Jazz Pharmaceuticals Inc. | $108 |
| Sk Life Science, Inc. | $90.31 |
| Compensation for services other than consulting (speaking, faculty) | $2,500 |
|---|---|
| Food and Beverage | $1,443 |
| Consulting Fee | $725 |
| Education | $28.63 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,500 |
| F. Hoffmann-la Roche AG Oct 28, 2025 | Consulting Fee | $725 |
| Amgen Inc. Aug 15, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $28.63 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 30 industry-funded studies in 2025, from 16 companies. The companies reported $1,458,148 in research payments for these studies, mostly to the institutions running them.
- A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Eli Lilly and Company · Completed · NCT06538116 - Alzheimer's Disease Master Pre Screener
Genentech, Inc. - Lu AF28996 in Participants With Parkinson's Disease (PD)
H. Lundbeck A S · Completed · NCT04291859 - An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
Novartis Pharmaceuticals Corporation - Study name not reported
Novo Nordisk As - A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB SA · Enrolling by invitation · NCT05076617 - A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimers Disease
AbbVie Inc. - A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer s Disease
AbbVie Inc. - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - Tronti Phase 3 Double Blind
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.